What is the mechanism of action of this treatment?

The most common treatments for breast cancer include hormone therapy, chemotherapy, targeted therapy, and immunotherapy. Hormone therapy works by blocking hormones like estrogen that can promote cancer growth. Chemotherapy uses drugs to kill rapidly dividing cancer cells. Targeted therapy, such as CDK4/6 inhibitors, interferes with specific molecules involved in cancer cell growth and survival. Immunotherapy helps the immune system recognize and attack cancer cells. These treatments are crucial for breast cancer patients as they offer personalized approaches that can improve outcomes and reduce side effects compared to traditional therapies. Early detection through screening, as promoted in the trial, enhances the effectiveness of these treatments by identifying cancer at a more treatable stage.

What side effects are associated with this type of intervention?

Common treatments for breast cancer include chemotherapy, tamoxifen, and aromatase inhibitors. Chemotherapy can cause side effects such as nausea, vomiting, diarrhea, and stomatitis. Tamoxifen, used for hormone receptor-positive breast cancer, may lead to hot flashes, increased risk of blood clots, and endometrial cancer. Aromatase inhibitors, another hormone therapy, can result in bone density loss, fractures, and cardiovascular risks. Imaging-based screening, such as mammography, is generally safe but can sometimes lead to false positives or negatives, causing unnecessary anxiety or missed diagnoses.

What prior FDA approvals exist?

The FDA has approved several treatments for breast cancer, particularly for HER2-positive metastatic breast cancer. Notable approvals include trastuzumab, which has shown significant benefits in progression-free survival, and its combination with other agents like lapatinib and aromatase inhibitors. The ALTERNATIVE trial demonstrated improved outcomes with a combination of lapatinib, trastuzumab, and an aromatase inhibitor. Additionally, the incorporation of CDK 4/6 inhibitors with endocrine and anti-HER2 therapy has been supported by trials like monarcHER. These approvals highlight the evolving landscape of breast cancer treatment, emphasizing targeted therapies and combination regimens to improve patient outcomes.

What other types of research exist?

Promising, novel alternatives to using advocates and supporters for increasing breast cancer screening rates include targeted educational interventions, such as culturally tailored breast health education programs, and the use of personalized communication strategies, like reminder letters or digital notifications. These approaches have shown effectiveness in increasing screening uptake and can be further optimized with advancements in technology and data analytics.

← Back to Search

Health Education & Support for Lung Cancer

N/A

Recruiting

Led By Ashley E Prosper

Research Sponsored by Jonsson Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Breast screening > 40

Be older than 18 years old

Must not have

Breast screening < 40

Lung screening < 50 or > 80

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

No Placebo-Only Group

Summary

This trial uses people who support or participate in breast and lung cancer screenings to encourage others to get screened for lung cancer. It targets patients eligible for lung cancer screening, especially those already involved in breast cancer screening. The goal is to reduce fear, stigma, and lack of awareness about lung cancer screening through education and personal interactions.

Who is the study for?

This trial is for people eligible for breast (over 40 years old) and lung cancer screening (ages 50-80), regardless of smoking status. Participants can be male or female and should have a close family or friend with a history of smoking. It excludes those under the age limits, previously diagnosed with lung cancer, recent unexplained weight loss, hemoptysis, or active cancer.

What is being tested?

The study tests if using advocates and supporters can increase lung cancer screening rates among eligible individuals. It involves health education programs, patient navigation services to guide through healthcare systems, and survey administration to gather data on psychological barriers unique to lung screening.

What are the potential side effects?

Since this trial focuses on educational interventions rather than medical treatments, there are no direct side effects like you would expect from drugs or surgeries. However, participants may experience discomfort discussing personal health issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am over 40 and have had a breast screening.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am under 40 and have had a breast screening.

Select...

I am younger than 50 or older than 80.

Select...

I have not had lung cancer, coughed up blood, or lost more than 15 pounds without trying in the last year.

Select...

I currently have active cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Increased rates of lung and breast cancer screening adherence

Secondary study objectives

Success of "sphere of influence" model

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Screening (electronic patient portal, patient navigation)Experimental Treatment4 Interventions

Participants access an electronic patient portal with educational materials at baseline, 1- and 2-year follow-ups, and also interact with a patient navigator on study. Patients also receive materials to share with their friends/family on benefits of breast and lung cancer screening on study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Patient Navigation

2017

Completed Phase 2

~38910

Health Education

2014

Completed Phase 3

~4410

0 / 5Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for breast cancer include hormone therapy, chemotherapy, targeted therapy, and immunotherapy. Hormone therapy works by blocking hormones like estrogen that can promote cancer growth. Chemotherapy uses drugs to kill rapidly dividing cancer cells. Targeted therapy, such as CDK4/6 inhibitors, interferes with specific molecules involved in cancer cell growth and survival. Immunotherapy helps the immune system recognize and attack cancer cells. These treatments are crucial for breast cancer patients as they offer personalized approaches that can improve outcomes and reduce side effects compared to traditional therapies. Early detection through screening, as promoted in the trial, enhances the effectiveness of these treatments by identifying cancer at a more treatable stage.

Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms.Clinical and histopathological features of carcinosarcoma of the renal pelvis: a systematic review of a rare tumor.Molecular-targeted first-line therapy for advanced gastric cancer.